Long term Therapeutic Effect of Intravitreal Bevacizumab on Myopic Choroidal Neovascularization

Moohwan Chang, Woohyung Cho, Minsoo Lee

Dankook University Hospital, Cheonan, Republic of Korea

Purpose: To evaluate the long term therapeutic effects of intravitreal injection of Bevacizumab for myopic choroidal neovascularization.

Methods: Six patients who underwent intravitreal bevacizumab injection for myopic CNV and were followed up for more than 2 years. Patient's records were retrospectively reviewed. The best corrected visual acuity was retrospectively assessed, from baseline to 1 , 3, 12, and 24 months after injection. Central macular thickness and fluorescein angiography were performed to evaluate the effects within 2 years

Results: The mean best corrected visual acuity was 1.16±0.43(logMAR), 0.45±0.21(logMAR), 0.29±0.23(logMAR), 0.14±0.11(logMAR), and 0.11±0.06(logMAR) at baseline, 1, 3, 12,and 24 months after injection. The average number of intravitreal injections administered was 1.33. The central foveal thickness significantly decreased from baseline to 24 months(350±65.1㎛ vs 248±36.6㎛, p=0.01). Fluorescein angiography showed no leakage of fluorescein.

Conclusion: Intravitreal bevacizumab injection was an effective in significantly increasing best corrected visual acuity and reducing central macular thickness. Intravitreal injection of bevacizumab seems to be effective with 2-year follow up.